CNS Drugs

, Volume 18, Issue 1, pp 49–55 | Cite as

Zotepine for Behavioural and Psychological Symptoms in Dementia

An Open-Label Study
  • Michael K. Rtainer
  • Hermann A. M. Mucke
  • Christine Krüger-Rainer
  • Manfred Haushofer
  • Sigfried Kasper
Original Research Article

Abstract

Objective: To provide initial information on the safety and efficacy of the atypical antipsychotic zotepine in the treatment of behavioural and psychological symptoms of dementia (BPSD).

Methods: This was an open-label, single-centre field study. Twenty-four patients with BPSD associated with Alzheimer’s disease (n = 12) or other forms of dementia (n = 12) were included. During the 8-week observation period, the patients received zotepine (Nipolept®) [12.5–150 mg/day] for the psychotic components of BPSD; no other treatment interventions for BPSD were allowed. At baseline, day 28 and day 56, patients were evaluated using the Clinical Global Impressions (CGI) scale; the Mini-Mental State Examination (MMSE), the Syndrome Brief Test (SKT) and the Age Concentration Test (AKT) to assess cognition; and the Neuropsychiatric Inventory (NPI) and the Cohen-Mansfield Agitation Inventory (CMAI) to assess BPSD. General adverse effects and, more specifically, the emergence of extrapyramidal symptoms were also assessed.

Results: There was no change from baseline to day 56 in the CGI score and the caregiver burden (as indcated by the caregiver-related section of the NPI). There was also no change in cognition (as assessed by the MMSE, SKT and AKT). The neuropsychiatric symptom score according to part 1 of the NPI (especially key psychotic symptoms, aggression and disinhibition) and the CMAI scores improved by 36% and 15%, respectively, between baseline and the end of the study in a highly statistically significant fashion.

No significant differences in treatment response or adverse effect profile were noted between the 12 patients with Alzheimer’s disease and the 12 patients with other types of dementia.

Zotepine was well tolerated, with tiredness and sedation (five and four cases, respectively) being the most frequent complaints. No clinically significant emergence of extrapyramidal symptoms was seen.

Conclusions: Zotepine appears to be well tolerated and effective in treating BPSD, consistent with the performance of other atypical antipsychotic drugs in this condition. Larger, controlled studies are warranted.

Keywords

Dementia Antipsychotic Drug Zolpidem Clinical Global Impression Extrapyramidal Symptom 

Notes

Acknowledgements

This study was supported by an unconditional research grant from EBEWE Pharma Ges.m.b.H, A-4866 Unterach, Austria. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 2000; 15: S2–4PubMedCrossRefGoogle Scholar
  2. 2.
    Margallo-Lana M, Swann A, O’Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16: 39–44PubMedCrossRefGoogle Scholar
  3. 3.
    Rainer M, Mucke HA, Masching A, et al. Non-cognitive symptom profiles in dementia: experience from psychiatric services and memory clinics. Psychiatr Prax 1999; 26: 71–5PubMedGoogle Scholar
  4. 4.
    Rojas-Fernandez CH, Lanctot KL, Allen DD, et al. Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? Pharmacotherapy 2001; 21: 74–102PubMedCrossRefGoogle Scholar
  5. 5.
    Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8: 29–34PubMedCrossRefGoogle Scholar
  6. 6.
    Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56: 1266–72PubMedCrossRefGoogle Scholar
  7. 7.
    Ballard C, Gray A, Ayre G. Psychotic symptoms, aggression and restlessness in dementia. Rev Neurol (Paris) 1999; 155Suppl. 4: S44–52Google Scholar
  8. 8.
    Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363–84PubMedCrossRefGoogle Scholar
  9. 9.
    Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry 2000; 61 Suppl. 8: 43–9Google Scholar
  10. 10.
    Needham PL, Atkinson J, Skill MJ, et al. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull 1996; 32: 123–8PubMedGoogle Scholar
  11. 11.
    Tatsumi M, Jansen K, Blakely RD, et al. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368: 277–83PubMedCrossRefGoogle Scholar
  12. 12.
    Kanba S, Yagi G, Oguchi E, et al. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain. Jpn J Psychiatry Neurol 1991; 45: 133–4PubMedGoogle Scholar
  13. 13.
    Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996; 32: 81–7PubMedGoogle Scholar
  14. 14.
    Fleischhacker WW, Barnas C, Stuppack CH, et al. Zotepine vs haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 1989; 25: 97–100PubMedGoogle Scholar
  15. 15.
    Sarai K, Okada M. Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study. Pharmacopsychiatry 1987; 20: 38–46PubMedCrossRefGoogle Scholar
  16. 16.
    Fleischhacker WW, Barnas C, Stuppack C, et al. Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 1987; 20: 58–60PubMedCrossRefGoogle Scholar
  17. 17.
    Barnas C, Stuppack CH, Miller C, et al. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial vs haloperidol. Int Clin Psychopharmacol 1992; 7: 23–7PubMedCrossRefGoogle Scholar
  18. 18.
    Kasper S, Quiner S, Barnas C, et al. Zotepine in the treatment of acute hospitalized schizophrenic episodes. Int Clin Psychopharmacol 2001; 16: 163–8PubMedCrossRefGoogle Scholar
  19. 19.
    Meyer-Lindenberg A, Gruppe H, Bauer U, et al. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997; 30: 35–42PubMedCrossRefGoogle Scholar
  20. 20.
    Harada T, Otsuki S. Antimanic effect of zotepine. Clin Ther 1986; 8: 406–14PubMedGoogle Scholar
  21. 21.
    McKhann G, Drachman DA, Folstein MF, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers’s Disease. Neurology 1985; 34: 939–44CrossRefGoogle Scholar
  22. 22.
    Folstein MF, Folstein S, McHugh R. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRefGoogle Scholar
  23. 23.
    Cummings JL. The neuropsychiatric inventory: assessing psychopathology in patients with dementia. Neurology 1997; 48: S10–6PubMedCrossRefGoogle Scholar
  24. 24.
    Lehfeld H, Erzigkeit H. The SKT: a short cognitive performance test for assessing deficits of memory and attention. Int Psychogeriatr 1997; 9: 115–21PubMedCrossRefGoogle Scholar
  25. 25.
    Gatterer G, Fischer P, Simanyi M, et al. The A-K-T (‘Alters-Konzentrations-Test’) a new psychometric test for geriatric patients. Funct Neurol 1989; 4: 273–6PubMedGoogle Scholar
  26. 26.
    Koss E, Weiner M, Ernesto C, et al. Assessing patterns of agitation in Alzheimer’s disease patients with the Cohen-Mansfield Agitation Inventory. Alzheimer Dis Assoc Disord 1997; 11: 45–50CrossRefGoogle Scholar
  27. 27.
    Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9PubMedCrossRefGoogle Scholar
  28. 28.
    Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol 1994; 51: 676–81PubMedCrossRefGoogle Scholar
  29. 29.
    Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer’s disease. Psychiatr Clin North Am 1991; 14: 353–73PubMedGoogle Scholar
  30. 30.
    McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997; 314: 266–70PubMedCrossRefGoogle Scholar
  31. 31.
    McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–8PubMedCrossRefGoogle Scholar
  32. 32.
    Devanand DP, Levy SR. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 8: S18–27Google Scholar
  33. 33.
    Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998; 351: 1032–3PubMedCrossRefGoogle Scholar
  34. 34.
    Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998; 155: 1512–20PubMedGoogle Scholar
  35. 35.
    Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Arch Neurol 1989; 46: 854–7PubMedCrossRefGoogle Scholar
  36. 36.
    Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147: 1640–5PubMedGoogle Scholar
  37. 37.
    Allain H, Dautzenberg PH, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl) 2000; 148: 361–6CrossRefGoogle Scholar
  38. 38.
    Kirchner V, Kelly CA, Harvey RJ. Thioridazine for dementia. Cochrane Database Syst Rev 2000; (2): CD000464 2000Google Scholar
  39. 39.
    De Deyn PP, Katz IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry 2000; 15Suppl. 1: S14–22PubMedGoogle Scholar
  40. 40.
    De Deyn PP, Rabhera K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53(5): 946–55PubMedCrossRefGoogle Scholar
  41. 41.
    Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial: Risperidone Study Group. J Clin Psychiatry 1999; 60(2): 107–15PubMedCrossRefGoogle Scholar
  42. 42.
    Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64(2): 134–43PubMedCrossRefGoogle Scholar
  43. 43.
    Clark WS, Street JS, Feldman PD, et al. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer’s disease. J Clin Psychiatry 2001; 62: 34–40PubMedCrossRefGoogle Scholar
  44. 44.
    Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999; 14: 459–66PubMedCrossRefGoogle Scholar
  45. 45.
    Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry 2002; 63 Suppl. 13: 21-6Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Michael K. Rtainer
    • 1
  • Hermann A. M. Mucke
    • 2
  • Christine Krüger-Rainer
    • 1
  • Manfred Haushofer
    • 1
  • Sigfried Kasper
    • 3
  1. 1.Memory Clinic and Psychiatric Department, DonauspitalSozialmedizinisches Zentrum OstViennaAustria
  2. 2.H.M. Pharma ConsultancyViennaAustria
  3. 3.Department of General PsychiatryUniversity of ViennaViennaAustria

Personalised recommendations